A unique collection of 378 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS); Targets include angiogenesis signaling, and related targets such as S1P, VEGFR, PDGF, etc.; Includes approved drugs targeting angiogenesis, such as Sunitinib Malate, Lenalidomide, sorafenib, Erlotinib; drugs in clinical development with the most potential targeting angiogenesis, such as Vatalanib, Orantinib, 2-Methoxyestradiol (Panzem), Celecoxib; Safety and effectiveness of the small molecules have been demonstrated through preclinical and clinical research; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality
